Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Schiffer JT, Swan DA, Corey L, Wald A.

Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9. doi: 10.1128/AAC.01114-13.

2.

Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.

Schiffer JT, Magaret A, Selke S, Corey L, Wald A.

J Antimicrob Chemother. 2011 Nov;66(11):2593-600. doi: 10.1093/jac/dkr346.

3.

Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.

Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F, Corey L.

Sex Transm Dis. 2006 Sep;33(9):529-33.

PMID:
16540883
4.

Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.

Leone P, Warren T, Hamed K, Fife K, Wald A.

Sex Transm Dis. 2007 Nov;34(11):900-7.

PMID:
17538513
5.

Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.

Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun-Vignes B, Ravaud P, Chosidow O.

Cochrane Database Syst Rev. 2014 Aug 3;(8):CD009036. doi: 10.1002/14651858.CD009036.pub2. Review.

PMID:
25086573
6.

Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L.

Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.

7.

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A.

Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Erratum in: Lancet. 2012 Feb 18;379(9816):616.

8.

Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. doi: 10.1073/pnas.1006614107.

9.

A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.

Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, Robinson NJ, Bassett MT, Wilson D, Brown DW, Hayes RJ.

Sex Transm Infect. 2008 Dec;84(7):548-53. doi: 10.1136/sti.2008.031153.

PMID:
18684855
10.

Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs.

Bernstein DI, Bravo FJ, Pullum DA, Shen H, Wang M, Rahman A, Glazer RI, Cardin RD.

Antivir Chem Chemother. 2015 Feb;24(1):19-27. doi: 10.1177/2040206614566581.

PMID:
26149263
11.
12.

The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women.

Strachan E, Saracino M, Selke S, Magaret A, Buchwald D, Wald A.

Brain Behav Immun. 2011 Oct;25(7):1475-81. doi: 10.1016/j.bbi.2011.06.003.

13.
14.

Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.

Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H.

Molecules. 2011 Aug 25;16(9):7210-23. doi: 10.3390/molecules16097210.

15.

Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.

Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer MC, Djagbaré D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group..

N Engl J Med. 2007 Feb 22;356(8):790-9.

16.

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.

Wald A, Zeh J, Barnum G, Davis LG, Corey L.

Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8-15.

PMID:
7503497
17.

Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.

Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, Miller G, Corey L.

J Infect Dis. 2004 Oct 15;190(8):1374-81.

18.

The pharmacological profile of famciclovir.

Crumpacker C.

Semin Dermatol. 1996 Jun;15(2 Suppl 1):14-26. Review.

PMID:
8840412
19.

Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug.

Chakrabarty A, Tyring SK, Beutner K, Rauser M.

Antivir Chem Chemother. 2004 Sep;15(5):251-3. Review.

PMID:
15535046
20.

A review of famciclovir in the management of genital herpes.

Faro S.

Infect Dis Obstet Gynecol. 1998;6(1):38-43. Review.

Items per page

Supplemental Content

Support Center